inspirator schreef op 24 februari 2018 11:13:
We have on the next slide please – we have great ambitions for the filgotinib’s profile based on the data generated so far in the Phase 2 studies in rheumatoid arthritis and in Crohn’s disease. We are very excited by filgotinib’s safety and tolerability profile which promises to be best in class. We believe this is due to a high selectivity for JAK1. With data from more than 2,000 patient year exposure to-date, we have been consistently impressed by the favorable safety and adverse event profile. We expect to present long-term data with up to 2 years of treatment from the DARWIN 3 open label study in rheumatoid arthritis patients at the upcoming ACR meeting this year.